Natriuretic peptides and cyclic guanosine 3',5'-monophosphate in asymptomatic acid symptomatic left ventricular dysfunction

Heart

Volumn 76, Issue 2, 1996, Pages 129-136

  Friedl, Walter ^b   Mair, Johannes ^a   Thomas, Steffen ^a   Pichler, Max ^b   Puschendorf, Bernd ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Ctr for Cardiac Rehab Grossgmain   (Austria)

Author keywords

Asymptomatic left ventricular dysfunction; Cyclic guanosine monophosphate; Natriuretic peptides; Radionuclide ventriculography

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP;

ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; EXERCISE; FEMALE; FUNCTIONAL ASSESSMENT; HEART DILATATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOISOTOPE VENTRICULOGRAPHY; SYMPTOM;

EID: 0029740696     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.76.2.129     Document Type: Article

References (32)

1. Rosenzweig A, Seidmann CE. Atrial natriuretic factor and related peptide hormones. Annu Rev Biochem 1991;60: 229-55.
2. Wei CM, Heublein DM, Perrella MA, Lerman A, Rodeheffer RJ, McGregor GY, et al. Natriuretic petide system in human heart failure. Circulation 1993;88: 1004-9.
3. Brandt RR, Wright RS, Redfield MM, Burnett JC. Atrial natriuretic peptide in heart failure. J Am Coll Cardiol 1993;22 suppl A:86A-92A.
4. Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circulation 1988;62:191-5.
5. Winters CJ, Sallman AL, Baker BJ, Meadows J, Rico DM, Vesely DL. The N-terminus and a 4,000-MW peptide from the midportion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation 1989;80: 438-49.
6. Wei CM, Kao PC, Lin JT, Heublein DM, Schaff HV, Burnett JC. Circulating β-atrial natriuretic factor in congestive heart failure in humans. Circulation 1993;88: 1016-20.
7. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. J Clin Invest 1991;87:1402-12.
8. Lang CC, Choy AM, Struthers AD. Atrial and brain natriuretic peptides - a dual natriuretic peptide system potentially involved in circulatory homeostasis. Clin Sci 1992; 83:519-27.
9. Song DL, Kohse KP, Murad F. Brain natriuretic factor. Augmentation of cellular cyclic GMP, activation of particulate guanylate cyclase and receptor binding. FEBS Lett 1988;232/1:125-9.
10. Hirata Y, Ishii M, Matsuoka H, Sugimoto T, Iizuka M, Uchida Y, et al. Plasma concentrations of α-human atrial natriuretic polypeptide and cyclic GMP in patients with heart disease. Am Heart J 1987;113:1463-69.
11. Vorderwinkler KP, Artner-Dworzak E, Jakob G, Mair J, Dienstl F, Pichler M, et al. Release of cyclic guanosine monophosphate evaluated as a diagnostic tool in cardiac disease. Clin Chem 1991,37:186-90.
12. Tsutamoto T, Kanamori T, Morigami N, Sugimoto Y, Yamaoka O, Kinoshita M. Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Circulation 1993;87:70-5.
13. Packer M. Pathophysiology of chronic heart failure. Lancet 1992;340:88-91.
14. Burnett JC, Kao PC, Hu DC, et al Atrial natriuretic peptide elevation in congestive heart failure in human. Science 1986;231:1145-7.
15. Haug C, Metzele A, Koch M, Hombach V, Grüner A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin Cardiol 1993;16:553-7.
16. Jakob G, Mair J, Vorderwinkler KP, Judmaier G, König P, Zwierzina H, Pichler M, Puschendorf B. Clinical significance of urinary cyclic guanosine monophosphate in diagnosis of heart failure. Clin Chem 1994;40/1:96-100.
17. Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic value of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989;13:1534-9.
18. Hall C, Kjekshus J, Eneroth P, Snapinn S. The plasma concentration of N-terminal proatrial natriuretic factor (ANF(1-98) is related to prognosis in severe heart failure. Clin Cardiol 1994;17:191-5.
19. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82:1730-6.
20. Hall C, Rouleau JL, Moyè L, de Champlain J, Bichet D, Klein M, Sussex B, Packer M. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Cirulation 1994;89: 1934-42.
21. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992;327:685-91.
22. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang C, Kubo SH, for the SOLVD Investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction. Circulation 1990;82:1724-9.
23. Lerman A, Gibbons RJ, Rodeheffer RJ, Bailey KR, McKinley LJ, Heublein DM, et al. Circulating N-terminal atrial natriuretic peptide as a marker for symtomless left-ventricular dysfunction. Lancet 1993;341:1105-9.
24. Motwani JG, McAlpine H, Kennedy N, Struthers AD. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 1993;341:1109-13.
25. Pichler M, Mostbeck G, Friedrich L, Eghbalian F, Gassner A. Scintigraphic left ventricular function during exercise in elderly patients with coronary artery disease. Eur Heart J 1984;5:55-7.
26. Jakob G, Mair J, Pichler M, Puschendorf B. Ergometric exercise improves the sensitivity of cyclic guanosine 3′5′-monophosphate to diagnose asymptomatic left ventricular dysfunction. Br Heart J 1995;73:145-50.
27. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental tool in clinical medicine. Clin Chem 1993;39/4:561-77.
28. Metz CE. Some practical issues of experimental design and data analysis in radiological ROC studies. Invest Radiol 1186;24:234-45.
29. Choy AMJ, Darbar D, Lang CC, Pringle TH, McNeill GP, Kennedy NSJ, et al. Detection ni left ventricular dysfunction alter acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J 1994;72:16-22.
30. Yasue H, Obata K, Okumura K, Kurose M, Ogawara H, Matsuyama K, et al. Increased secretion ot atrial natriuretic polypeptide from the left ventricle in patients with dilated cardiomyopathy. J Clin Invest 1989;83:46-51.
31. Chaidahl K, Hedner J, Hedner T. Atrial natriuretic peptide and catecholamines in periphereal blood as indicators of cardiac dysfunction in the general population. Clin Sci 1988;74:587-94.
32. Wallen T, Landahl S, Hedner T, Hedner J, Hall C. Atrial peptides, ANP(1 98 and ANP(99 126) in health and disease in an elderly population. Eur Heart J 1993;14: 1508-13.